Background: Drug-resistant tuberculosis (DR-TB) remains a serious health challenge due to prolonged treatment duration, pill burden, and declining success rates. The Bedaquiline, Pretomanid, and Linezolid (BPaL) regimen offers a promising alternative with shorter treatment duration and potentially fewer side effects. This study aims to provide clinical characteristics, recovery rate, and outcomes of BPaL regimen administration in DR-TB patients. Methods: This descriptive quantitative study was conducted at Persahabatan Hospital, involving 35 DR-TB patients treated with the BPaL regimen between 2022 and 2024. Secondary data were collected from medical records accessed via simrspersahabatan.co.id on April 17, 2024. Data included patient demographics, clinical signs and symptoms, treatment history, side effects, success rate, culture conversion, and patient’s compliance. Data analysis was conducted in three stages: reduction (filtering relevant data), presentation (using tables, graphs, and descriptive narration), and conclusion drawing (interpreting patterns and comparing with relevant literature). Statistical analysis was performed using Google Sheets. Results: The average age of patients was 43 years, with normal BMI, pre-XDR-TB status, comorbid diabetes mellitus, and a history of previous TB treatment. Common clinical symptoms included productive cough, shortness of breath, and hemoptysis. The treatment success rate reached 94.3%, with most patients achieving culture conversion within three months and demonstrating high treatment compliance. Adverse effects were mostly grade 2, including respiratory symptoms, peripheral neuropathy, nausea, and vomiting. Conclusion: This research shows that a positive clinical picture can increase the successful recovery of DR-TB patients, with a high success rate of BPaL regimen, minimal side effects, and patient compliance with treatment until completion.